MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "MAO-B inhibitors"

  • 2022 International Congress

    Central fatigue and glutamatergic overactivity in Parkinson’s disease: possible impact of safinamide

    C. Pauletti, N. Locuratolo, D. Mannarelli, A. Maffucci, A. Petritis, F. Fattapposta (Rome, Italy)

    Objective: The aim of the present study was to test the hypothesis that central fatigue in Parkinson’s disease (PD) could be related to high levels…
  • 2022 International Congress

    Improvement of movement disorder and neurodevelopment under selegiline in a CLTC deficient patient

    F. Nardecchia, L. Pannone, F. Manti, V. Muto, R. Bove, L. Pollini, M. Giannini, M. Tartaglia, S. Martinelli, V. Leuzzi (Rome, Italy)

    Objective: We report the significative improvement on both movement disorder and neurodevelopment in a 5-year-old CLTC deficient patient treated with selegiline. Background: In 2019 we described a 30-year-old woman…
  • 2022 International Congress

    SAFINAMIDE: REAL LIFE STUDY. EFFICACY IN SWITCH FROM RASAGILINA AND LOW-DOSE TREATMENT.

    MI. Morales-Casado, N. López-Ariztegui, DD. García-Meléndez, A. Diezma-Martín (Toledo, Spain)

    Objective: Evaluate the efficacy of safinamide in fluctuations in Parkinson's disease in real life. Analysis by subgroups: Switch rasagiline to safinamide and treatment with low…
  • 2022 International Congress

    Safinamide adherence: the experience of the movement disorder unit of Trieste.

    M. Catalan, M. Liccari, V. Tommasini, L. Antonutti, P. Manganotti (Trieste, Italy)

    Objective: Describe the clinical experience with Safinamide and assess the patients’ adherence to this treatment in the movement disorders centre of Trieste-Italy. Background: Safinamide (Xadago®)…
  • MDS Virtual Congress 2021

    Effects of safinamide adjunct therapy on non-motor symptoms in patients with Parkinson’s disease: a post-hoc analysis of the Japanese Phase 2/3 study

    N. Hattori, Y. Tsuboi, Y. Kogo, M. Koebisu, T. Ishida, I. Suzuki, M. Nomoto (Tokyo, Japan)

    Objective: To evaluate the efficacy of safinamide for mood and pain by a post-hoc analysis of the Japanese phase 2/3 double-blind study (JapicCTI-153056) in patients…
  • MDS Virtual Congress 2021

    Safinamide Improves Sleep and Daytime Sleepiness in Parkinson´s Disease. Results from the SAFINONMOTOR Study

    I. Cabo López, C. Labandeira Guerra, R. Yáñez Baña, MI. Cimas Hernando, JM. Paz González, MG. Alonso Losada, MJ. González Palmás, C. Martínez Miró, D. Santos García (Pontevedra, Spain)

    Objective: Our aim was to analyze the effectiveness of safinamide on sleep in Parkinson´s disease (PD) patients from the SAFINONMOTOR (an open-label study of the…
  • MDS Virtual Congress 2021

    Safinamide Improves Mood in Parkinson´s Disease. Results from the SAFINONMOTOR Study.

    C. Labandeira, MG. Alonso Losada, R. Yáñez Baña, I. Cimas Hernando, I. Cabo López, JM. Paz González, MJ. González Palmás, C. Martínez Miró, D. Santos García (Vigo, Spain)

    Objective: Our aim was to analyze the effectiveness of safinamide on mood in Parkinson´s disease (PD) patients from the SAFINONMOTOR (an open-label study of the…
  • MDS Virtual Congress 2021

    Improved Excessive Daytime Sleepiness with Selegiline in patients with Parkinson’s Disease: An Open Trial

    JR. Zhang, JP. Chen, J. Li, J. Li, CJ. Mao, CF. Liu (Suzhou, China)

    Objective: This study, an open-labeled trial, was aimed to assess the efficacy and safety of selegiline on the treatment of EDS in PD patients. Background: Excessive Daytime…
  • MDS Virtual Congress 2020

    Treatment characterization and decision-making strategy for first-line pharmacological motor symptomatic therapies in Parkinson’s disease

    M. Javidnia, J. Jones, A. Ertefaie, C. Venuto (Rochester, NY, USA)

    Objective: (1) To characterize motor therapeutic use in the Parkinson’s Progression Markers Initiative (PPMI) early, untreated (de novo) cohort, and (2) to develop an evidence-based…
  • MDS Virtual Congress 2020

    The Effect of Rasagiline on Motor and Non-Motor Symptoms in Parkinson’s Disease

    B.G Koçer, E.A Özturk, SS. Çomoğlu (Ankara, Turkey)

    Objective: In this study, we aimed to evaluate the effect of rasagiline treatment on motor and non-motor symptoms in patients with Parkinson’s disease (PD). Background:…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley